GlobalHealth Asia-Pacific recognises Amaris B. Clinic as the Gynecomastia Clinic of the Year in Asia Pacific 2022
The award is a recognition of excellence among medical providers in the Asia Pacific region, as acknowledged by leading professionals in healthcare providers and organisations in the sector. SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- Amaris B. Clinic, led by Dr Ivan Puah, MOH accredited liposuction doctor and Chairman of Lipo Peer Review Committee in Singapore, was awarded "Gynecomastia...
TikoMed’s ILB(R) inhibits cell infection by coronaviruses and modulates reactive cytokine release from microglia in vitro
Adds further support for its broad-spectrum mechanism of action following other recent TBI, ALS and tropical virus studies VIKEN, Sweden, Sept. 13, 2022 /PRNewswire/ -- TikoMed today announced the inclusion in bioRxiv* of an in vitro study evaluating the ability of the company's lead drug candidate ILB® to: inhibit infection of human cells by the NL63 coronavirus...
SmartFuture’s White-label Remote Patient Monitoring Platform goes global
SINGAPORE, Sept. 13, 2022 /PRNewswire/ -- SmartFuture's white-label Remote Patient Monitoring (RPM) platform is now being deployed successfully in 11 countries, including Singapore, Malaysia, other ASEAN countries, India and most recently, in the United States. According to Sumit Khemani, CEO, "We are seeing increasing adoption across markets. In Asia, providers are increasingly realizing the potential benefits of remote patient...
German Chancellor Scholz, WHO Director-General Tedros, international ministers at World Health Summit 2022
Press accreditation open for the world's leading global health conference BERLIN, Sept. 13, 2022 /PRNewswire/ -- The World Health Summit and the World Health Organization (WHO) as co-organizer jointly invite to the world's leading global health conference. The World Health Summit 2022 from October 16-18 in Berlin will bring together the most prominent names in global health from all...
First and only TIGIT/TGF-β dual-targeting antibody fusion protein of Akeso demonstrated promise in preclinical results published at ESMO
HONG KONG, Sept, 13, 2022 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso"), a China-based biopharmaceutical company focusing on the development and commercialization of innovative therapeutic antibodies for Oncology & Immunology, published encouraging preclinical results in poster featuring its Fc-mutant anti-TIGIT antibody fused with TGF-βRII protein (AK130) at the European Society for Medical...
Microtech to unveil implantable microsensor technology at 34th Transcatheter Cardiovascular Therapeutics (TCT) annual meeting
TEL AVIV, Israel, Sept. 13, 2022 /PRNewswire/ -- Microtech, a wholly owned subsidiary of Medinol, Inc., a leader in global MedTech research and development, announced that its implantable microsensor platform will be presented at the 34th Transcatheter Cardiovascular Therapeutics (TCT), the annual scientific symposium of the Cardiovascular Research Foundation on Friday, September...
CStone announces China’s NMPA has accepted and granted priority review to the supplemental new drug application (sNDA) for sugemalimab in the treatment of patients with relapsed or refractory extranodal...
This is the third supplemental new drug application (NDA) that CStone has submitted for sugemalimab after the prior two for stage III and IV non-small cell lung cancer. Sugemalimab has the potential to become the world's first immuno-oncology therapy to be approved for patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (R/R ENKTL). GEMSTONE-201 is the largest...
Transcenta Releases Encouraging Interim Safety and Efficacy Data of the TST001 (Osemitamab) and Chemotherapy Combination Expansion Cohort for First Line Claudin18.2 Positive Gastric Cancer at ESMO Congress 2022
In first line treatment of advanced or metastatic G/GEJ cancer, early interim data of the first 15 patients with measurable disease receiving the combination of TST001 (Osemitamab) with CAPOX demonstrated a partial response rate of 73.3% and a disease control rate of 100% per RECIST1.1. Based on these encouraging data, the TST001 (Osemitamab) program is further accelerated and...
Starpharma presents compelling data in Prostate Cancer at ESMO
MELBOURNE, Australia, Sept. 13, 2022 /PRNewswire/ -- Cabazitaxel (Jevtana, Sanofi) is a market leading chemotherapy for the treatment of advanced prostate cancer (mCRPC). Developed by Australian biotech company Starpharma, DEP® cabazitaxel is a patented, highly water soluble dendrimer nanoparticle version of standard cabazitaxel which has shown, in preclinical and clinical studies, benefits in terms of safety and efficacy. Positive...
NCCN’s New Patient Guidelines for Marginal Zone Lymphoma Help Patients and Caregivers Better Understand a Rare Form of Blood Cancer
An evidence-based, expert consensus resource, available for free at NCCN.org/patientguidelines, helps people understand a rare and complex cancer type PLYMOUTH MEETING, Pa., Sept. 13, 2022 /PRNewswire/ -- The National Comprehensive Cancer Network® (NCCN®) has published new NCCN Guidelines for Patients®: Marginal Zone Lymphoma. A cancer of the lymphatic system, marginal zone lymphoma (MZL)...
